Aprea Therapeutics (APRE)
(Delayed Data from NSDQ)
$3.13 USD
+0.21 (7.19%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $3.13 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth A Momentum F VGM
Price, Consensus and EPS Surprise
APRE 3.13 +0.21(7.19%)
Will APRE be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for APRE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for APRE
Aprea Therapeutics, Inc. (APRE) Reports Q2 Loss, Tops Revenue Estimates
Liquidia Technologies, Inc. (LQDA) Reports Q2 Loss, Lags Revenue Estimates
APRE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Jazz Pharma (JAZZ) Gets EU Nod for Cancer Drug Enrylaze
FDA Accepts Merck (MRK) sNDA for Welireg in Renal Cell Carcinoma
Bears are Losing Control Over Aprea Therapeutics, Inc. (APRE), Here's Why It's a 'Buy' Now
Other News for APRE
Aprea Therapeutics to Present at the Life Sciences Investor Forum on September 19
UPDATE - Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
Aprea Therapeutics management to meet virtually with B. Riley